Effect of Prostaglandins on the Regulation of Tumor Growth
Journal:
Current Medicinal Chemistry - Anti-Cancer Agents
Volume:
4
Page:
379-387
Author(s):
Shunji Ishihara, M A.K. Rumi, Toshihiko Okuyama and Yoshikazu Kinoshita
Cytochrome P450 Gene Polymorphism and Cancer
Journal:
Current Drug Metabolism
Volume:
5
Page:
211-224
Author(s):
Jose A.G. Agundez
Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1885-1905
Author(s):
Simone Boldt and Walter Kolch
MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1907-1914
Author(s):
Judith S. Sebolt-Leopold
Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1915-1922
Author(s):
Reinhard Wetzker and Christian Rommel
The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1923-1936
Author(s):
A- R. Hanauske, Karen Sundell and Michael Lahn
Monitoring Therapy with Gene Expression Profiling Reveals Physiological Differences in Drug Action
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1959-1968
Author(s):
S. Wolfl, A. Burchert and T. C. Kroll
The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1739-1744
Author(s):
Christopher S. Navara
SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1745-1756
Author(s):
A. Y. Tsygankov and S. K. Shore
Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1757-1766
Author(s):
A. O. Vassilev and F. M. Uckun